| 包装: | 1mg |
| 规格: | 98% |
| 市场价: | 3038元 |
| 分子量: | 405.9 |
Background:
Levofloxacin-d8 is intended for use as an internal standard for the quantification of levofloxacin by GC- or LC-MS. Levofloxacin is a fluoroquinolone antibiotic and the active stereoisomer of ofloxacin .1 It is active against S. aureus, S. epidermidis, B. subtilis, E. coli, P. aeruginosa, and K. pneumoniae (MICs = 0.25, 0.25, 0.5, 0.03, 4, and 0.25 μg/ml, respectively).2 Levofloxacin inhibits S. aureus DNA gyrase and topoisomerase IV (IC50s = 8.06 and 9.81 μg/ml, respectively).3 It eliminates infection in rat models of endocarditis caused by methicillin-sensitive or -resistant S. aureus.4 Formulations containing levofloxacin have been used in the treatment of various bacterial infections.
|1. Norrby, S.R. Levofloxacin. Expert Opin. Pharmacother. 1(1), 109-119 (1999).|2. Mohammadhosseini, N., Alipanahi, Z., Alipour, E., et al. Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety. Daru. 20(1), (2012).|3. Takei, M., Fukuda, H., Kishii, R., et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45(12), 3544-3547 (2001).|4. Entenza, J.M., Vouillamoz, J., Glauser, M.P., et al. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41(8), 1662-1667 (1997).
m.cnreagent.com